SI1502599T1 - Use of mutated VEGF for antiangiogenic therapy - Google Patents

Use of mutated VEGF for antiangiogenic therapy

Info

Publication number
SI1502599T1
SI1502599T1 SI200332037T SI200332037T SI1502599T1 SI 1502599 T1 SI1502599 T1 SI 1502599T1 SI 200332037 T SI200332037 T SI 200332037T SI 200332037 T SI200332037 T SI 200332037T SI 1502599 T1 SI1502599 T1 SI 1502599T1
Authority
SI
Slovenia
Prior art keywords
antiangiogenic therapy
mutated vegf
vegf
mutated
antiangiogenic
Prior art date
Application number
SI200332037T
Other languages
Slovenian (sl)
Inventor
Romero Monica Bequet
Castro Boris Ernesto Acevedo
Cowley Jorge Victor Gavilondo
Molina Luis Enrique Fernandez
Ocejo Omar Lopez
Rodriguez Ricardo De La Caridad Silva
Lasa Alexis Musachio
Rodriguez Ernesto Galban
Blomquist Dania Marcia Vazquez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of SI1502599T1 publication Critical patent/SI1502599T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
SI200332037T 2002-04-15 2003-04-11 Use of mutated VEGF for antiangiogenic therapy SI1502599T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20020076A CU23178A1 (en) 2002-04-15 2002-04-15 ANTIANGIOGEN ACTIVE ACTIVE IMMUNOTHERAPY
PCT/CU2003/000004 WO2003086450A1 (en) 2002-04-15 2003-04-11 Active antiangiogenic therapy
EP03711811A EP1502599B1 (en) 2002-04-15 2003-04-11 Use of mutated VEGF for antiangiogenic therapy

Publications (1)

Publication Number Publication Date
SI1502599T1 true SI1502599T1 (en) 2011-10-28

Family

ID=40134850

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332037T SI1502599T1 (en) 2002-04-15 2003-04-11 Use of mutated VEGF for antiangiogenic therapy

Country Status (17)

Country Link
US (3) US7556809B2 (en)
EP (1) EP1502599B1 (en)
JP (1) JP4741800B2 (en)
KR (1) KR100704127B1 (en)
CN (1) CN1646153B (en)
AR (1) AR039285A1 (en)
AT (1) ATE511851T1 (en)
AU (1) AU2003218603B2 (en)
CA (1) CA2480079C (en)
CU (1) CU23178A1 (en)
DK (1) DK1502599T3 (en)
ES (1) ES2365329T3 (en)
PT (1) PT1502599E (en)
RU (1) RU2329824C2 (en)
SI (1) SI1502599T1 (en)
WO (1) WO2003086450A1 (en)
ZA (1) ZA200408460B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23178A1 (en) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech ANTIANGIOGEN ACTIVE ACTIVE IMMUNOTHERAPY
CN103073620B (en) * 2002-09-12 2014-12-10 肿瘤疗法科学股份有限公司 KDR peptides and vaccines comprising the same
EP1804835B9 (en) * 2004-09-13 2010-09-29 Genzyme Corporation Multimeric constructs
EP2289533B1 (en) * 2005-02-28 2013-09-18 Oncotherapy Science, Inc. Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
US20060234941A1 (en) * 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
CN103638522A (en) 2006-01-18 2014-03-19 通用医疗公司 Methods of increasing lymphatic function
CN101394857A (en) * 2006-02-01 2009-03-25 爱吉恩公司 Composite for treating cancer containing oligonucleotide and nontoxic LPS
KR101493775B1 (en) * 2007-02-16 2015-02-16 온코세라피 사이언스 가부시키가이샤 Vaccine therapy for choroidal neovascularization
RU2488592C2 (en) * 2007-08-08 2013-07-27 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Peptides of directed action of vegfr-1/nrp-1
TWI436775B (en) * 2007-08-24 2014-05-11 Oncotherapy Science Inc Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent
WO2009132268A1 (en) * 2008-04-24 2009-10-29 3M Innovative Properties Company Analysis of nucleic acid amplification curves using wavelet transformation
CN102272307A (en) * 2008-11-21 2011-12-07 利莱恩斯生命科学有限公司 Inhibition of vegf-a secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of vegf-c and rhoa
JP5539411B2 (en) 2009-03-04 2014-07-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Compositions containing angiogenic factors and methods of use thereof
TW201109029A (en) * 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
SI2601214T1 (en) 2010-08-06 2018-03-30 Genzyme Corporation Vegf antagonist compositions and uses thereof
RU2444378C1 (en) * 2010-09-06 2012-03-10 Олег Германович Макеев Method of treating coronary insufficiency in simulated myocardial ischemia
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
WO2013074820A1 (en) * 2011-11-16 2013-05-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immunogenic tumor associated stromal cell antigen peptides and methods of their use
KR102205077B1 (en) * 2012-08-31 2021-01-20 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Dna vaccine containing vegf-specific epitope and/or angiopoietin-2-specific epitope
WO2015110701A1 (en) * 2014-01-21 2015-07-30 University Of Helsinki Therapeutic use of vegfr-3 ligands
KR101509047B1 (en) * 2014-07-28 2015-04-08 한국생명공학연구원 Method for diagnosing and screening asthma using Neuropilin １
CN109071630B (en) 2016-01-15 2022-05-31 马里兰大学帕克分校 Endo-S2 mutant as glycoside synthase, method for production and use for glycoengineering of glycoproteins
US10787497B2 (en) 2016-07-05 2020-09-29 Ibentrus, Inc. Cancer treatment composition for inhibiting tumor angiogenesis, containing VEGF deep blocker
WO2018031734A1 (en) 2016-08-10 2018-02-15 University Of Maryland, College Park DESIGNER α1,6-FUCOSIDASE MUTANTS ENABLE DIRECT CORE FUCOSYLATION OF INTACT N-GLYCOPEPTIDES AND N-GLYCOPROTEINS
JP7168228B2 (en) * 2017-05-19 2022-11-09 慶應義塾 Peptide vaccine and peptide vaccine composition for cranial nerve disease
US10836815B2 (en) 2017-06-29 2020-11-17 University Of Maryland, College Park Generation and comparative kinetic analysis of new glycosynthase mutants from Streptococcus pyogenes endoglycosidases for antibody glycoengineering
WO2020151666A1 (en) * 2019-01-25 2020-07-30 四川大学华西医院 Biomarker for hemangioma treament

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
CA2158745C (en) * 1993-03-25 2007-06-19 Richard L. Kendall Inhibitor of vascular endothelial cell growth factor
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
EP1032583A4 (en) * 1998-03-06 2005-02-02 Imclone Systems Inc Active immunization against angiogenesis-associated antigens
WO1999057981A1 (en) * 1998-05-08 1999-11-18 Sloan-Kettering Institute For Cancer Research Compositions and methods for active vaccination
AU776473C (en) * 1999-03-11 2005-04-14 Entremed, Inc Compositions and methods for treating cancer and hyperproliferative disorders
EP1252177A1 (en) * 2000-02-04 2002-10-30 Supratek Pharma, Inc. Ligand for vascular endothelial growth factor receptor
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
CU23178A1 (en) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech ANTIANGIOGEN ACTIVE ACTIVE IMMUNOTHERAPY

Also Published As

Publication number Publication date
PT1502599E (en) 2011-08-03
CU23178A1 (en) 2006-09-22
ZA200408460B (en) 2005-08-30
US8883724B2 (en) 2014-11-11
AU2003218603B2 (en) 2009-05-28
US7556809B2 (en) 2009-07-07
US20080254050A1 (en) 2008-10-16
US20100047265A1 (en) 2010-02-25
CN1646153B (en) 2017-05-24
DK1502599T3 (en) 2011-08-01
RU2329824C2 (en) 2008-07-27
CA2480079C (en) 2013-07-30
ES2365329T3 (en) 2011-09-29
KR100704127B1 (en) 2007-04-05
JP4741800B2 (en) 2011-08-10
JP2006501145A (en) 2006-01-12
US20050175624A1 (en) 2005-08-11
ATE511851T1 (en) 2011-06-15
CN1646153A (en) 2005-07-27
KR20040111526A (en) 2004-12-31
CA2480079A1 (en) 2003-10-23
AU2003218603A1 (en) 2003-10-27
WO2003086450A1 (en) 2003-10-23
EP1502599B1 (en) 2011-06-08
AR039285A1 (en) 2005-02-16
EP1502599A1 (en) 2005-02-02
RU2004133338A (en) 2005-06-10

Similar Documents

Publication Publication Date Title
SI1502599T1 (en) Use of mutated VEGF for antiangiogenic therapy
IL175042A0 (en) Photodynamic therapy for local adipocyte reduction
AU2003216162A8 (en) Iontophoretic treatment device
AU2003270437A8 (en) Mediated electrochemical oxidation of inorganic materials
IL166266A0 (en) Use of reboxetine for the treatment of hot flashes
GB0204525D0 (en) Medical therapy apparatus
EP1566197A4 (en) Iontophoresis apparatus
GB0207411D0 (en) Azole compounds and their therapeutic use
PL375561A1 (en) Therapeutic use
EP1478356A4 (en) Therapeutic compounds
AU2003217754A8 (en) New methods of using antiangiogenic agents
GB0223744D0 (en) Electrodes for therapeutic apparatus
TW561896U (en) Phototherapy apparatus
GB2392909B (en) Portable sewage treatment unit
GB0229986D0 (en) Treatment of materials
GB0216128D0 (en) New therapeutic use
GB0229744D0 (en) New therapeutic use
GB0220064D0 (en) New therapeutic use
GB0222478D0 (en) New therapeutic use
GB0300146D0 (en) Therapeutic device
TW576211U (en) Electric pulse therapeutic shoes
GB0223118D0 (en) Therapeutic use
GB0226850D0 (en) Therapeutic use
GB0226865D0 (en) Therapeutic use
GB0219721D0 (en) Therapeutic compounds